MK-677 is not another name for sermorelin
MK-677, also called ibutamoren, and sermorelin are different active ingredients. FDA identifies ibutamoren as a growth hormone secretagogue that has not been approved by the agency. An oral product described as MK-677 should not be read as an oral version of sermorelin. [1]
That distinction matters before you compare convenience or cost. Write down the ingredient exactly as it appears on the proposed prescription, including any combination ingredients. A broad label such as “growth hormone support” leaves too much unanswered. Our guide to injection, oral and nasal options explains why route alone is also an incomplete comparison.
Their approval histories do not transfer
Sermorelin was the active ingredient in Geref. FDA’s 2013 notice addressed specific former Geref injection products and concluded they had not been withdrawn for safety or effectiveness reasons. That product-specific finding does not establish approval for a current compounded adult wellness product, and it says nothing about approval of ibutamoren. [2]
Compounded medicines are not FDA-approved and do not undergo the agency’s premarket evaluation for safety, effectiveness or quality. FDA on compounded-drug risks.[3] Our sermorelin approval guide covers the historical distinction in more detail. Ask what applies to the actual product being offered today, rather than accepting the history of a related name.
Read the MK-677 trial beyond the muscle headline
A randomized trial enrolled 65 healthy adults aged 60–81. At one year, fat-free mass increased by 1.1 kg with MK-677 and declined by 0.5 kg with placebo. The change did not translate into improved strength or function; fasting glucose increased and insulin sensitivity decreased. The authors identified the small sample and limited duration as constraints. [4]
This is useful evidence about that study, not a head-to-head comparison with sermorelin. It cannot tell you which drug would produce a better personal outcome. In particular, do not turn “fat-free mass” into “stronger,” or assume results in older volunteers establish benefits in younger adults. Read our guide to biomarkers and outcomes before interpreting a hormone result as proof of a treatment benefit.
Safety findings depend on the population
A separate randomized study of 123 older people recovering from hip fracture was stopped early after a congestive-heart-failure safety signal. Although IGF-1 rose, most functional measures did not improve. The investigators described an unfavorable safety profile in that population. [5]
That finding should neither be concealed nor converted into a numerical risk estimate for an entirely different patient. FDA also warns that ibutamoren may affect glucose metabolism and fluid retention, with potential heart-failure risk in certain people and unknown long-term effects. FDA’s ibutamoren warning.[1] A clinician needs your medical and medication history to discuss what those uncertainties mean for you.
The useful comparison is a consultation, not a winner
Bring three questions: What exact condition or goal is being addressed? What evidence supports this ingredient and formulation for someone like me? What would make you reconsider the plan? Ask the clinician to distinguish expected laboratory changes from outcomes you would notice in daily life.
Then compare the service separately: initial evaluation, pharmacy, follow-up, total charges and cancellation rules. Those details belong in your consultation checklist even when the treatment decision remains open. A subscription price should not settle a clinical question, and a research citation should not substitute for a clear explanation of the prescription.
Sources
- FDA. Ibutamoren safety information in the Agebox iKids Growth Day Formula notification. September 23, 2025.↩ 1 ↩ 2
- FDA. Geref withdrawal determination. Federal Register, March 4, 2013.↩
- FDA. Understanding the Risks of Compounded Drugs.↩
- Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149:601–611. doi:10.7326/0003-4819-149-9-200811040-00003.↩
- Adunsky A et al. MK-0677 for patients recovering from hip fracture: randomized phase IIb study. Arch Gerontol Geriatr. 2011;53:183–189. doi:10.1016/j.archger.2010.10.004.↩